REDWOOD CITY, California, May 9, 2017 /PRNewswire/ — C2 Therapeutics marked Digestive Disease Week by releasing the results of clinical studies that help further validate the utility of the C2 CryoBalloon® Ablation System (CbAS) for ablation of Barrett’s esophagus.i
http://www.prnewswire.co.uk/news-releases/studies-further-validate-safety-efficacy-and-an-improved-patient-experience-in-use-of-the-c2-cryoballoon-ablation-system-for-primary-treatment-of-barretts-esophagus-621726663.html
Studies Further Validate Safety, Efficacy And An Improved Patient Experience In Use Of The C2 CryoBalloon® Ablation System For Primary Treatment Of Barrett’s Esophagus